Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

McCullough et al., The American Journal of Medicine, doi:10.1016/j.amjmed.2020.07.003
Aug 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Review of pathophysiological principles related to early outpatient treatment and therapeutic approaches including reduction of reinoculation, combination antiviral therapy, immunomodulation, antiplatelet/antithrombotic therapy, and administration of oxygen, monitoring, and telemedicine.
Proposes an algorithm based on age and comorbidities that allows for a large proportion to be monitored and treated at home during self-isolation with the aim of reducing the risks of hospitalization and death.
McCullough et al., 6 Aug 2020, peer-reviewed, 23 authors.
This PaperHCQAll
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
MD, MPH, Baylor Peter A Mccullough, MD Ronan J Kelly, MD Gaetano Ruocco, MD Edgar Lerma, MD James Tumlin, MD Kevin R Wheelan, MD Nevin Katz, MD Norman E Lepor, MD Kris Vijay, MD Harvey Carter, MD Bhupinder Singh, BS Sean P Mccullough, MD Brijesh K Bhambi, MD Alberto Palazzuoli, MD Gaetano M De Ferrari, MD, MPH Gregory P Milligan, MD, MPH Taimur Safder, PhD Kristen M Tecson, MD Dee Dee Wang, MD John E Mckinnon, MD William W O'neill, MD Marcus Zervos, MD, PhD Harvey A Risch
The American Journal of Medicine, doi:10.1016/j.amjmed.2020.07.003
Approximately 9 months of the severe acute respiratory syndrome coronavius-2 (SARS-CoV-2 [COVID-19]) spreading across the globe has led to widespread COVID-19 acute hospitalizations and death. The rapidity and highly communicable nature of the SARS-CoV-2 outbreak has hampered the design and execution of definitive randomized, controlled trials of therapy outside of the clinic or hospital. In the absence of clinical trial results, physicians must use what has been learned about the pathophysiology of SARS-CoV-2 infection in determining early outpatient treatment of the illness with the aim of preventing hospitalization or death. This article outlines key pathophysiological principles that relate to the patient with early infection treated at home. Therapeutic approaches based on these principles include 1) reduction of reinoculation, 2) combination antiviral therapy, 3) immunomodulation, 4) antiplatelet/antithrombotic therapy, and 5) administration of oxygen, monitoring, and telemedicine. Future randomized trials testing the principles and agents discussed will undoubtedly refine and clarify their individual roles; however, we emphasize the immediate need for management guidance in the setting of widespread hospital resource consumption, morbidity, and mortality.
References
Ackermann, Verleden, Kuehnel, Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19, N Engl J Med, doi:10.1056/NEJMoa2015432
Ailani, Agastya, Ailani, Mukunda, Shekar, Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia, Arch Intern Med, doi:10.1001/archinte.159.3.266
Argenziano, Bruce, Slater, Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series, BMJ, doi:10.1136/bmj.m1996
Arshad, Kilgore, Chaudhry, Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.099
Artifoni, Danic, Gautier, Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors, J Thromb Thrombolysis, doi:10.1007/s11239-020-02146-z
Bhandari, Rankawat, Bagarhatta, Clinico-radiological evaluation and correlation of CT chest images with progress of disease in COVID-19 patients, J Assoc Physicians India
B€ Osm€ Uller, Traxler, Bitzer, The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation
Chan, Slim, Shaaban, Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease
Chen, Effects of ambient temperature and humidity on droplet lifetime -A perspective of exhalation sneeze droplets with COVID-19 virus transmission, Int J Hyg Environ Health, doi:10.1016/j.ijheh.2020.113568
Coomes, Haghbayan, Favipiravir, an antiviral for COVID-19?, J Antimicrob Chemother, doi:10.1093/jac/dkaa171
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.13136
Eljaaly, Alshehri, Aljabri, Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis, BMC Infect Dis, doi:10.1186/s12879-017-2495-5
Gopalakrishnan, Mossaid, Lo, Vasudevan, Mccullough et al., Fulminant acute kidney injury in a young patient with novel coronavirus 2019, Cardiorenal Med, doi:10.1159/000508179
Han, Ma, Li, Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors, Emerg Microbes Infect, doi:10.1080/22221751.2020.1770129
Hsiang, Allen, Annan-Phan, The effect of large-scale anticontagion policies on the COVID-19 pandemic, Nature, doi:10.1038/s41586-020-2404-8
Izzedine, Jhaveri, Perazella, COVID-19 therapeutic options for patients with kidney disease, Kidney Int, doi:10.1016/j.kint.2020.03.015
Kolilekas, Loverdos, Giannakaki, Can steroids reverse the severe COVID-19 induced "cytokine storm
Lagier, Million, Gautret, Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101791
Li, Zhang, Wu, Wang, Zhao, The mechanism and clinical outcome of patients with corona virus disease 2019 whose nucleic acid test has changed from negative to positive, and the therapeutic efficacy of favipiravir: a structured summary of a study protocol for a randomised controlled trial, Trials, doi:10.1186/s13063-020-04430-y
Malek, Granwehr, Kontoyiannis, Doxycycline as a potential partner of COVID-19 therapies, IDCases, doi:10.1016/j.idcr.2020.e00864
Mccullough, Eidt, Rangaswami, Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection, Rev Cardiovasc Med, doi:10.31083/j.rcm.2020.01.42
Mcfadyen, Stevens, Peter, The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications:[published online ahead of print, Circ Res, doi:10.1161/CIRCRESAHA.120.317447
Mestre, Omez, Lorente-Ramos, Rogado, Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis
Mikami, Miyashita, Yamada, Risk Factors for Mortality in Patients with COVID-19 in New York City
Million, Lagier, Gautret, Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101738
Moores, Tritschler, Brosnahan, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease
Nussbaumer-Streit, Mayr, Dobrescu, Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review, Cochrane Database Syst Rev, doi:10.1002/14651858.CD013574
Pani, Lauriola, Romandini, Scaglione, Macrolides and viral infections: focus on azithromycin in COVID-19 pathology, Int J Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106053
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?, J Virus Erad
Prasad, Fitzgerald, Bao, Beck, Chandrasekar, Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, doi:10.7326/0003-4819-133-4-200008150-00006
Rahman, Idid, Can Zn Be a Critical Element in COVID-19 Treatment?
Risch, Early outpatient treatment of symptomatic, high-risk covid-19 patients that should be ramped-up immediately as key to the pandemic crisis
Rosenberg, Dufort, Udo, Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Schrezenmeier, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol, doi:10.1038/s41584-020-0372-x
Shojaei, Salari, COVID-19 and off label use of drugs: an ethical viewpoint, doi:10.1007/s40199-020-00351-y
Singh, Majumdar, Singh, Misra, Role of corticosteroid in the management of COVID-19: a systemic review and a clinician's perspective, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.06.054
Sodhi, Etminan, therapeutic potential for tetracyclines in the treatment of COVID-19 pharmacotherapy, doi:10.1002/phar.2395
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haem, doi:10.1111/jth.14817
Turshudzhyan, Anticoagulation options for coronavirus disease 2019 (COVID-19)-induced coagulopathy, Cureus, doi:10.7759/cureus.8150
Uller, Mair, Saalm€, Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study, Influenza Other Respir Viruses, doi:10.1111/irv.12421
Vaduganathan, Van Meijgaard, Mehra, Joseph, Donnell et al., Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States, JAMA, doi:10.1001/jama.2020.9184
Velthuis, Van Den Worm, Sims, Baric, Snijder et al., Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture, PLoS Pathog, doi:10.1371/journal.ppat.1001176
Westafer, Elia, Medarametla, Lagu, A transdisciplinary COVID-19 early respiratory intervention protocol: an implementation story, J Hosp Med, doi:10.12788/jhm.3456
Worldometer, COVID-19 coronavirus pandemic
Xu, Liu, Wu, Ali, Du et al., Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection, Clin Infect Dis, doi:10.1093/cid/ciaa790
Yang, Barnard, Emert, Clinical characteristics of patients with coronavirus disease 2019 (COVID-19) receiving emergency medical services in King County, Washington, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.14549
Zelenko, Clinical dx protocol
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit